CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia
Status:
Recruiting
Trial end date:
2024-02-04
Target enrollment:
Participant gender:
Summary
Patients with acute leukemia derived from T lymphocytes have the characteristics of high
expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to
genetically modify the patient's T lymphocytes to target and eliminate tumor cells in a major
histocompatibility complex-independent manner. CAR-T cells are costimulatory molecules that
include single-chain antibodies (scFv) that recognize tumor-specific antigens, hinge regions,
transmembrane regions, intracellular signaling regions (immunoreceptor tyrosine activation
motif ITAM), and intracellular signaling regions. The chimeric antigen receptor of CD28 or
CD137(4-1BB) conduction domain is expressed in a lentiviral vector, and the vector is
transfected into autologous T cells, so that the modified CAR-T cells have targeting and
specificity Recognizes and kills cancer cells expressing tumor antigens, and can proliferate
and activate in vivo, but has no effect on cells that do not express the antigen
Phase:
N/A
Details
Lead Sponsor:
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Collaborator:
The First Affiliated Hospital of Soochow University